PharmaMar initiates a pivotal Phase III ATLANTIS study with PM1183 in SCLC

(Pharmamar) PharmaMar today announced the start of a pivotal Phase III ATLANTIS study evaluating efficacy and safety of PM1183 in combination with doxorubicin versus topotecan or the combination VCR in patients with small cell lung cancer after the failure of one prior platinum-containing line.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news